4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Cabaletta Bio, Inc. (CABA) operates in the Biotechnology industry and is headquartered in Philadelphia, United States with about 156 employees. Its market capitalization is roughly $452 million. In the fiscal year ended 2025-12-31, CABA reported $0M in revenue and ($168M) in net income.
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($172M) | ($125M) | ($75M) | ($54M) |
| Net Income | ($168M) | ($116M) | ($68M) | ($53M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($44M) | ($43M) | ($47M) | ($46M) | ($37M) | — |
| Net Income | ($44M) | ($42M) | ($45M) | ($45M) | ($36M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $165M | $185M | $254M | $117M | — |
| Total Liabilities | $53M | $33M | $18M | $12M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CABA viewer.
About TickerBase · Data methodology & sources